# Cibus, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cibus, Inc.). ## Overview Cibus, Inc. develops gene-edited plant traits using its proprietary RTDS platform, with a current focus on weed-management traits for rice and canola. The company also pursues partner-funded sustainable ingredients and other trait programs, monetizing its technology through collaboration agreements, licenses, and future royalties rather than selling finished farm products. ## Products & services • RTDS gene editing platform for plant trait development • Rice herbicide tolerance traits and stacked trait lines • Canola and WOSR trait development programs • Soybean HT2 trait development • Partner-funded sustainable ingredients and biofragrance programs - **Gene editing platform** (0%) — Core RTDS technology used to edit elite germplasm with targeted trait changes. - **Rice traits** (45%) — Herbicide tolerance and stacked trait lines for rice commercialization. - **Canola and WOSR traits** (15%) — Trait development for canola and winter oilseed rape, including disease resistance work. - **Soybean traits** (10%) — Soybean editing programs such as HT2 used to expand the platform and future partnerships. - **Sustainable ingredients and biofragrance** (30%) — Partner-supported ingredient and fermentation-based product development programs. - RTDS gene editing platform for precise plant trait edits - Rice herbicide tolerance traits for weed management - Canola and WOSR trait development programs - Soybean HT2 trait development - Partner-funded sustainable ingredients program - Bio-based fermentation biofragrance products ## Customers Cibus sells primarily to seed companies, agricultural partners, and prospective commercial licensees that want trait-enabled germplasm rather than a finished consumer product. Its rice program is being advanced with prospective customers in rice-growing geographies, while sustainable ingredients and biofragrance work is partly funded by a consumer-packaged goods partner. Revenue today is driven by collaboration agreements, contract research, and development support rather than broad commercial product sales. - **Seed companies and breeding partners** (primary) — Buy trait access and edited germplasm to incorporate Cibus traits into commercial seed lines. - **Agricultural collaboration partners** (primary) — Fund contract research and development milestones for rice, canola, and other traits. - **Consumer-packaged goods partner** (secondary) — Supports sustainable ingredients development and helps fund commercialization work. - **Prospective rice commercial customers** (primary) — Engage for rice herbicide tolerance traits in geographies where rice is cultivated globally. - **Future licensees and royalty partners** (emerging) — Would commercialize products containing Cibus intellectual property and pay fees or royalties. - Seed companies seeking licensed traits for elite germplasm - Rice growers' value chain partners in Latin America and the U.S. - Agricultural collaborators funding trait R&D milestones - Consumer-packaged goods partner supporting ingredients work - Future licensees seeking herbicide tolerance and disease resistance traits ## Geography Cibus is headquartered in the United States and conducts development work across the U.S. and international agricultural markets. Recent regulatory validation in the United States, Ecuador, and the UK supports its commercialization path, while Latin America is becoming important for rice trait rollout through the Semillano collaboration. The company also references future expansion into the U.S. and broader global rice-growing regions, making regulatory frameworks a key geographic driver of timing and market access. - United States is the home market and a key regulatory reference point - Ecuador provided regulatory validation for RTDS technologies - Latin America is a near-term rice commercialization focus - UK regulatory progress may lower barriers for precision-bred organisms - Global rice-growing geographies are the target market for future launches ## Strategy Cibus is narrowing its focus to weed management in rice and partner-supported sustainable ingredients to preserve capital and improve execution. The company is pushing its RTDS platform through regulatory validation and field trials so it can move edited traits into customer germplasm and commercial launches. Cost reductions, facility rationalization, and workforce streamlining are intended to reduce cash burn and extend runway while the company advances toward initial commercialization. - **Commercialize rice herbicide tolerance traits** (short-term) — Rice is the clearest near-term path to revenue and customer adoption. - **Convert RTDS validation into broader regulatory acceptance** (medium-term) — Lower regulatory barriers should shorten development cycles and expand addressable markets. - **Preserve capital and reduce burn** (short-term) — The company remains loss-making and needs runway to reach commercialization milestones. - **Monetize partner-funded sustainable ingredients** (medium-term) — This provides non-dilutive funding and diversifies the revenue base. - Focus capital on rice weed-management traits - Advance RTDS edits into customer elite germplasm - Use regulatory wins to accelerate market access - Expand Latin America first, then the U.S. - Keep partner-funded ingredients work moving with limited capital - Reduce cash burn through restructuring and facility rationalization ## Risks Cibus remains an early-commercial biotech company with limited revenue, ongoing losses, and dependence on external funding and partner support. Its strategy is concentrated in rice and a few adjacent programs, so delays in regulation, customer adoption, or trait performance could materially affect execution and cash needs. The company also faces restructuring-related operational risk, litigation exposure, and the usual agricultural biotech risks around field trial outcomes, competitor innovation, and market acceptance. - **Financing and liquidity risk** [high] — The company has incurred losses since inception and expects continued losses before commercialization scales. - **Commercialization delay in rice traits** [high] — Revenue depends on moving edited traits into customer germplasm and achieving regulatory clearance and adoption. - **Restructuring execution risk** [medium] — Workforce and facility reductions may reduce institutional knowledge and disrupt development. - **Regulatory risk** [high] — Gene-edited crop commercialization depends on evolving rules in each market. - **Litigation and contingent liability risk** [medium] — The company accrued a liability related to a Ninth Circuit decision and insurance proceeds repayment. - Ongoing losses and limited cash create financing and runway risk - Rice commercialization depends on regulatory and customer adoption timing - Restructuring may cause attrition and loss of institutional knowledge - Trait development can fail in field trials or miss performance targets - Litigation liability and other contingencies can create unexpected cash outflows ## Accounting Cibus is a loss-making development-stage company, so reported results are heavily affected by judgmental estimates, restructuring charges, and impairment testing. Revenue is still small and driven by collaboration and contract research, making timing of milestone and service recognition important for quarter-to-quarter comparability. Investors should also watch goodwill impairment, litigation accruals, and going-concern disclosures because they can materially affect reported losses and balance-sheet presentation. - **Revenue recognition for collaboration agreements** — Quarterly revenue volatility - **Goodwill impairment** — Non-cash operating loss volatility - **Litigation liability accrual** — Balance sheet liability and earnings impact - **Going concern and liquidity estimates** — Disclosure risk and investor perception of runway - **Restructuring and lease exit accounting** — Expense timing and cash usage - Collaboration and contract research revenue timing affects quarterly comparability - Goodwill impairment can create large non-cash charges - Litigation accruals affect liabilities and operating results - Going-concern assessment reflects funding and runway uncertainty - Restructuring costs and lease exit decisions affect cash burn and expense timing --- *Last updated: 2026-04-28T19:57:49.846001+00:00*